<DOC>
	<DOCNO>NCT00771433</DOCNO>
	<brief_summary>RATIONALE : G-CSF may prevent reduce febrile neutropenia woman receive chemotherapy breast cancer . It yet know G-CSF regimen effective prevent neutropenia . PURPOSE : This phase II trial study well G-CSF work prevent neutropenia woman receive chemotherapy breast cancer .</brief_summary>
	<brief_title>G-CSF Preventing Neutropenia Women Receiving Chemotherapy Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Evaluate efficacy filgrastim ( G-CSF ) prevent hematological toxicity woman breast cancer receive neoadjuvant adjuvant chemotherapy . Secondary - Compare actual v theoretical dose intensity . OUTLINE : This multicenter study . Patients stratify accord age ( &lt; 65 year vs â‰¥ 65 year ) prior chemotherapy ( adjuvant v neoadjuvant ) . Patients assign 1 2 group . - Group 1 : Patients receive filgrastim ( G-CSF ) subcutaneously ( SC ) daily day 6-11 course chemotherapy primary prophylaxis . Chemotherapy course repeat every three week 3-6 course . - Group 2 : Patients receive G-CSF SC daily day 6-11 course chemotherapy primary prophylaxis . Chemotherapy course repeat every three week 3-6 course . Patients may also receive secondary prophylaxis G-CSF experience episode neutropenia .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Neutropenia</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis breast cancer Receiving 1 follow neoadjuvant adjuvant chemotherapy regimen : Six course epirubicin hydrochloride docetaxel Six course fluorouracil , epirubicin hydrochloride , cyclophosphamide ( FEC ) 100 3 course FEC 100 3 course docetaxel 100 Must receive least 2 chemotherapy regimen prior study therapy No malignant hematological disease Hormone receptor status specify PATIENT CHARACTERISTICS : Menopausal status specify Not pregnant nursing Fertile patient must use effective contraception No contraindication standard neoadjuvant adjuvant chemotherapy No known hypersensitivity GCSF components No patient deprive liberty guardianship No psychological , familial , social , geographical reason prevent followup PRIOR CONCURRENT THERAPY : See Disease Characteristics No concurrent participation another experimental drug study</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2008</verification_date>
	<keyword>neutropenia</keyword>
	<keyword>chemotherapeutic agent toxicity</keyword>
	<keyword>recurrent breast cancer</keyword>
	<keyword>stage I breast cancer</keyword>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>stage IIIC breast cancer</keyword>
	<keyword>stage IV breast cancer</keyword>
</DOC>